Baidu
map

Nat Biot:液体活检新突破!科学家们开发出“RNA测序”的通用模板

2018-07-20 浮苏 生物探索

通过检测血液或尿液中少量的RNA来诊断或治疗疾病是一个新兴领域。随着技术的进步,研究人员可以对RNA片段进行测序,但不同的人使用不同的方法来测序RNA,有时会得到不同的结果,这是影响成功的一个重大障碍,使得此领域很难取得进展。近来,密歇根大学Tewari教授的实验室领导了美国和荷兰的9个实验室组成联盟,通过美国国立卫生研究院,试图解决这个问题。该联盟测试了9种不同的RNA测序方法,以了解和标准化测

基于RNA的液体活检主要依赖于对小RNA测序的能力,例如microRNA。这些微小的细胞碎片可以在癌症等疾病中发生改变,为早期发现疾病提供线索。但是,血液或尿液只含有少量的细胞外RNA,这使得测序变得更具挑战性。

Tewari教授说:“RNA液体活检是一个令人兴奋的诊断新领域。因为不同的方法可能会带来不同的结果,所以这个领域需要一个联盟。”他还指出,这项工作的优势在于将不同的专业知识汇集在一起,从分子生物学家到生物信息学专家。

7月16日,这项在自然生物技术杂志上发表的题为“Comprehensive multi-center assessment of accuracy, reproducibility and bias of small RNA-seq methods for quantitative miRNA profilin”的研究中,科学家们对样本进行了相同的准备,并将其送往全球的9个实验室进行分析。每个实验室使用9种不同的测试方法对四个不同的样本(一个血浆样本和三个合成RNA样本)进行测序。最终,他们共获得超50亿的测序结果。

“我们发现,不仅不同的方法产生不同的结果,而且在同一测序方法中,任何微小的变化都会带来一个显著的变化。该研究的主要作者、Tewari实验室的博士后研究员Maria D. Giraldez说:“为了比较各实验室结果之间的差异,我们需要一套通用、高度标准化的方法指南。”

Tewari实验室的Ryan Spengler博士后研究员说:“如果你在多个实验室使用相同的方法,结果就不会有太大的变化。”“这意味着,如果你想在不同的实验室之间协调一项研究,关键是要遵守同样的方法。”

由联盟实验室开发的方法提高了液体活检的准确性。当用RNA测序来比较不同样本之间个体microRNA的相对数量时,所有的方法都产生了准确和可重复的估计。该研究为创建标准程序的方法奠定了基础,并推动RNA测序和液体活检领域的进步。

研究人员已经制作出了综合参考材料,这意味着全国的研究人员都可以按照他们的方法进行测试,并将结果与实验室联盟发现的结果进行比较。Tewari的实验室正在继续致力于改进方法,以便更有效地发现生物标记物。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1724986, encodeId=73081e24986a3, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Thu Jun 27 19:46:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918204, encodeId=3834191820461, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 10 20:46:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883197, encodeId=2902188319e86, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 30 11:46:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278100, encodeId=b98212e81006e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Jul 22 00:46:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516810, encodeId=a90b1516810ef, content=<a href='/topic/show?id=eb451556289' target=_blank style='color:#2F92EE;'>#RNA测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15562, encryptionId=eb451556289, topicName=RNA测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b3411016716, createdName=ms24272190615788285182, createdTime=Sun Jul 22 00:46:00 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1724986, encodeId=73081e24986a3, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Thu Jun 27 19:46:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918204, encodeId=3834191820461, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 10 20:46:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883197, encodeId=2902188319e86, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 30 11:46:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278100, encodeId=b98212e81006e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Jul 22 00:46:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516810, encodeId=a90b1516810ef, content=<a href='/topic/show?id=eb451556289' target=_blank style='color:#2F92EE;'>#RNA测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15562, encryptionId=eb451556289, topicName=RNA测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b3411016716, createdName=ms24272190615788285182, createdTime=Sun Jul 22 00:46:00 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
    2018-09-10 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1724986, encodeId=73081e24986a3, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Thu Jun 27 19:46:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918204, encodeId=3834191820461, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 10 20:46:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883197, encodeId=2902188319e86, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 30 11:46:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278100, encodeId=b98212e81006e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Jul 22 00:46:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516810, encodeId=a90b1516810ef, content=<a href='/topic/show?id=eb451556289' target=_blank style='color:#2F92EE;'>#RNA测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15562, encryptionId=eb451556289, topicName=RNA测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b3411016716, createdName=ms24272190615788285182, createdTime=Sun Jul 22 00:46:00 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1724986, encodeId=73081e24986a3, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Thu Jun 27 19:46:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918204, encodeId=3834191820461, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 10 20:46:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883197, encodeId=2902188319e86, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 30 11:46:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278100, encodeId=b98212e81006e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Jul 22 00:46:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516810, encodeId=a90b1516810ef, content=<a href='/topic/show?id=eb451556289' target=_blank style='color:#2F92EE;'>#RNA测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15562, encryptionId=eb451556289, topicName=RNA测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b3411016716, createdName=ms24272190615788285182, createdTime=Sun Jul 22 00:46:00 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1724986, encodeId=73081e24986a3, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Thu Jun 27 19:46:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918204, encodeId=3834191820461, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 10 20:46:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883197, encodeId=2902188319e86, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 30 11:46:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278100, encodeId=b98212e81006e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Jul 22 00:46:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516810, encodeId=a90b1516810ef, content=<a href='/topic/show?id=eb451556289' target=_blank style='color:#2F92EE;'>#RNA测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15562, encryptionId=eb451556289, topicName=RNA测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b3411016716, createdName=ms24272190615788285182, createdTime=Sun Jul 22 00:46:00 CST 2018, time=2018-07-22, status=1, ipAttribution=)]

相关资讯

EGFR-TKI耐药后的检测标本选择:组织活检vs.液体活检

奥希替尼是一种不可逆的三代EGFR-TKI,可以选择性地抑制EGFR敏感突变和T790M耐药突变。2017年3月,奥希替尼在华上市,开创了EGFR TKI耐药后T790M阳性患者的精准治疗新时代。随着泰瑞沙的上市,如何敏感、准确地检测T790M突变成为临床关注的热点。

多位专家指导:如何提取和研究血液DNA,RNA与蛋白

为了帮助大家更好的分离囊泡、提取RNA、存储样本和分析数据,The Scientist杂志与多位专家学者探讨了检测不同血液生物学指标的策略,贡献出了相应的注意事项和实验技巧。

Cancer Cell:了解肺癌,这个血液指标很关键!

荷兰的研究人员设计了不同的液体活检方法。通过检测血液循环血小板(也称为血栓细胞)吸收的肿瘤RNA,他们的测试(称为thromboSeq)不是在血液中寻找癌症DNA或其他生物标志物的证据,而是可以以接近90%的准确度诊断非小细胞肺癌。非小细胞肺癌占肺癌的绝大多数。该研究在8月14日刊登在癌症细胞杂志上。

Baidu
map
Baidu
map
Baidu
map